Viata offers hotel booking and comparative pricing for users.
Pacific Northwest Research Institute is a research institute for genetics and bioinformatics research.
Monod Bio is a life sciences company based in Seattle, Washington, focused on developing innovative biosensors for detecting proteins, toxins, antibodies, and other analytes. Founded in 2021, the company has created a biosensor platform that integrates binding, transduction, and amplification processes in a single step, allowing for the rapid and sensitive detection of a diverse array of target molecules. By leveraging recent advancements in computational protein engineering, Monod Bio has designed highly modular bio-sensing nanoswitches that facilitate cost-effective analytical assays. This technology aims to enhance the capabilities of the healthcare industry in biotechnology and medicine.
SEngine Precision Medicine, Inc. is a Seattle-based company that specializes in personalized cancer treatments through innovative technology. Founded in 2015, the company utilizes a proprietary search engine that combines functional genomics with robotic testing of cancer drugs on live patient organoids. This approach allows for the simultaneous testing of over 200 drugs against a patient’s unique tumor organoid, providing insights into the most effective and least toxic treatment options that traditional DNA sequencing may not reveal. By leveraging anonymized test results, SEngine not only empowers patients and oncologists with tailored treatment options but also aids in the development of new cancer-fighting drugs, positioning itself as a leader in the next generation of oncology diagnostics.
Cyrus Biotechnology, Inc. specializes in developing software tools for protein structure prediction and design, aiming to enhance research in biotechnology and pharmaceuticals. The company's flagship product, Rosetta, allows for the design of biologically active proteins that can address critical health issues, such as brain cancer treatment and gluten breakdown in Celiac Disease patients. Additionally, Cyrus Bench offers an enterprise version of the Rosetta toolkit, equipped with a variety of bio-molecular computation tools. The company also provides Cyrus CryoEM services, which include advanced structure refinement and model building. Founded in 2014 and headquartered in Seattle, Washington, Cyrus Biotechnology serves a diverse clientele, including pharmaceutical companies, venture-backed startups, and mid-sized biotech firms focused on therapeutic discovery and industrial biotechnology innovation.
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
AdaptX is a healthcare data analytics and AI company that specializes in enhancing clinical and workflow outcomes for hospitals and surgery centers. Founded in Seattle in 2016 as a spin-off from Seattle Children's Hospital, AdaptX provides a platform that enables medical leaders and clinicians to access and analyze clinical data effectively. The platform integrates algorithms with existing electronic data systems, allowing healthcare providers to monitor performance, compare treatment approaches, and define patient cohorts. Through automated analytics, AdaptX helps healthcare service providers improve the quality and safety of care while also reducing costs.
Medcurity is a developer of a compliance management platform used to perform complex HIPAA and security requirements for healthcare systems. Its platform enables users to build or complement their HIPAA privacy and security program with the intuitive tools and helpful guides available.
A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.
AdaptX is a healthcare data analytics and AI company that specializes in enhancing clinical and workflow outcomes for hospitals and surgery centers. Founded in Seattle in 2016 as a spin-off from Seattle Children's Hospital, AdaptX provides a platform that enables medical leaders and clinicians to access and analyze clinical data effectively. The platform integrates algorithms with existing electronic data systems, allowing healthcare providers to monitor performance, compare treatment approaches, and define patient cohorts. Through automated analytics, AdaptX helps healthcare service providers improve the quality and safety of care while also reducing costs.
Absci is a drug and target discovery company that utilizes deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. By employing its Integrated Drug Creation Platform, Absci identifies novel drug targets and discovers optimal biotherapeutic candidates while simultaneously generating the necessary cell lines for manufacturing. This innovative approach allows biotech and pharmaceutical partners to develop next-generation protein-based drugs, including Bionic Proteins that incorporate nonstandard amino acids and other unique drug designs that may be unattainable through traditional methods. Absci's mission focuses on advancing the development of improved medicines by effectively translating innovative ideas into viable drugs.
Phase Genomics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing innovative technology for genome assembly and metagenome deconvolution, focusing on its ProxiMeta Hi-C platform. This platform empowers researchers in various fields, including agriculture, human health, and industrial biology, by enabling the cultivation-independent assembly of bacterial genomes. By exploiting the structure of DNA, Phase Genomics aims to provide scientists with the most complete and accurate genomes and metagenomes possible, facilitating transformative discoveries and advancements in their respective areas of study.
Phytelligence is a product-focused technology company that develops and provides smart plants and solutions to growers, nurseries, and horticultural experts. It provides custom genetic analysis services that assess the similarity or dissimilarity of closely related samples. The company provides plants free of diseases, viruses, and pests. Its portfolio includes the Geneva series, Gisela series, and Krymsk series of rootstocks. Phytelligence was founded in 2012 by Amit Dhingra, and it is based in Pullman, Washington.
Rodeo Therapeutics is a drug development company focused on novel enzyme target and biological pathway that play a critical role in tissue repair and regeneration. Rodeo’s initial goal is to develop novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant.
Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that specializes in the development and manufacture of proteins and enzymes for various applications, including pharmaceuticals, polymers, and industrial chemicals. Founded in 2008, Arzeda utilizes advanced technology that combines physics-based protein design with artificial intelligence algorithms to create and validate new designer proteins and enzymes. The company aims to provide innovative solutions that offer competitive performance, cost efficiency, and sustainability, addressing the needs of clients in diverse industries.
WiBotic provides the most reliable wireless power and battery intelligence solutions to charge your aerial, mobile and aquatic robot systems. Using WiBotic wireless power and battery intelligence solutions, you can greatly enhance the working efficiency of your robot fleets and save significant money in charging and maintenance costs. Our solutions include wireless power delivery, battery intelligence and fleet-level power management software. So we not only maximize the battery life of each battery we charge, we create an operational plan for the entire collection of batteries in your robot fleet. WiBotic wireless power and battery intelligence solutions are safe, reliable and scalable. And they are easy-to-implement and highly customizable for specific robot deployments.
HyperSciences, Inc. develops advanced drilling solutions for various applications, including energy, tunneling, transportation, and aerospace. Founded in 2014 and headquartered in Spokane, Washington, with an additional office in Austin, Texas, the company offers innovative technologies such as HyperDrill, which enhances the rate of penetration in oil, gas, and geothermal drilling by up to ten times compared to conventional methods. HyperSciences also provides a geothermal solution that utilizes HyperDrill to access deep geothermal energy deposits and the HyperBreaker, a rock-breaking solution designed for construction, mining, and tunneling. By employing low-cost chemical energy to propel projectiles to hypersonic speeds, the company's technology enables faster and deeper penetration into hard rock, effectively addressing challenges in drilling and tunneling operations.
ApoGen Biotechnologies, Inc., founded in 2014 and located in Seattle, Washington, is dedicated to developing innovative therapeutics aimed at addressing the challenges of cancer treatment, particularly the issue of drug resistance. The company focuses on targeting the key drivers of genomic mutations in cancer cells, which are central to tumor evolution and the development of resistance to existing therapies. By addressing the chronic mutations in cancer genomes, ApoGen aims to improve treatment efficacy, reduce cancer recurrence and metastasis, and enhance overall patient survival. The company's approach represents a shift from traditional therapies, providing new hope in the ongoing battle against cancer.
Nexgenia develops and manufactures proprietary stimuli-responsive polymers and polymer-containing magnetic nanoparticles. These polymers change state from soluble single macromolecules to large insoluble aggregates in response to very modest changes (like temperature, pH, and salt) in their environment. When these polymers are attached to other chemicals/biologicals, they confer the same environmentally-responsive characteristics. Thus the resulting combinations can be small when it is advantageous to be small and large when that facilitates separation and analysis. This property enables the development of faster, more complete molecular/cellular separations and faster, more sensitive immunoassays. Nexgenia was founded in 2011 and is headquartered in Seattle, Washington.
AAVogen is a biotech startup that develops gene therapeutics for muscle wasting diseases. This includes muscular dystrophy, inflammatory myopathies and cancer cachexia. We make you stronger.
AnswerDash, Inc. is a Seattle-based company that offers a cloud-based Q&A platform designed to provide contextual answers to customers on websites, web applications, and mobile experiences. Founded in 2012 and originally known as Qazzow, Inc., the company allows businesses to integrate self-service features that enable customers to obtain answers through a point-and-click interface, facilitating easy access to information without cluttering web pages. By predicting user questions based on the content of the page, AnswerDash helps reduce support costs and enhances customer engagement. The platform can also integrate with live chat services to offer personalized assistance. As of June 2020, AnswerDash operates as a subsidiary of CloudEngage, Inc.
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.
C-SATS provides a personalized surgical skills assessment platform using a unique combination of data analytics, artificial intelligence. It specializes in the fields of robotic surgery, surgical skills, surgical insights, laparoscopic surgery, and minimally invasive surgery. The company was founded in 2014 and headquartered in Seattle, Washington.
Cardeas Pharma is focused on developing a novel antibiotic formulation that combines two drugs to effectively target highly resistant Gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, as well as carbapenem-resistant Enterobacteriaceae. This formulation is also effective against biofilms and Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). The antibiotics are delivered through a single-patient use nebulizer that produces small, uniform aerosol droplets, allowing for targeted delivery to the small airways and alveoli. By integrating this innovative antibiotic formulation with advanced drug-delivery technology, Cardeas Pharma aims to improve clinical outcomes for patients suffering from serious, hospital-acquired respiratory infections.
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.
FlexMinder, Inc. is a Seattle-based company that develops enterprise software solutions aimed at private health exchanges, health carriers, and third-party administrators (TPAs). Founded in 2011, FlexMinder focuses on automating the healthcare reimbursement process, enhancing the management of medical spending for flexible spending accounts. The company aggregates healthcare information from various sources to streamline claims submission, significantly reducing manual processing time and costs for TPAs. By providing online tools for managing the reimbursement process, FlexMinder aims to improve the user experience for consumers utilizing their flexible spending arrangements. In 2013, the company secured $1.4 million in Series AA financing to support its growth initiatives and was selected for the TechStars incubator program. As of January 2017, FlexMinder operates as a subsidiary of Jelleyvision Lab Inc.
Skytap, Inc. specializes in providing cloud-based development and testing environments aimed at migrating and modernizing enterprise applications globally. The company's primary offering, Skytap Cloud, allows for self-service access to production-like environments, facilitating more frequent code testing for development and testing teams. Skytap’s platform supports organizations in transitioning to modern software delivery methods by enabling the rapid migration of traditional workloads to the cloud and fostering the adoption of agile and DevOps practices. This approach helps businesses enhance their application development efficiency and integrate new cloud architectures. Additionally, Skytap provides a range of services including cloud migration, application modernization, training, and strategic consulting. Founded in 2006 and headquartered in Seattle, Washington, Skytap also maintains locations in Toronto, Canada, and London, United Kingdom.
AnswerDash, Inc. is a Seattle-based company that offers a cloud-based Q&A platform designed to provide contextual answers to customers on websites, web applications, and mobile experiences. Founded in 2012 and originally known as Qazzow, Inc., the company allows businesses to integrate self-service features that enable customers to obtain answers through a point-and-click interface, facilitating easy access to information without cluttering web pages. By predicting user questions based on the content of the page, AnswerDash helps reduce support costs and enhances customer engagement. The platform can also integrate with live chat services to offer personalized assistance. As of June 2020, AnswerDash operates as a subsidiary of CloudEngage, Inc.
FlexMinder, Inc. is a Seattle-based company that develops enterprise software solutions aimed at private health exchanges, health carriers, and third-party administrators (TPAs). Founded in 2011, FlexMinder focuses on automating the healthcare reimbursement process, enhancing the management of medical spending for flexible spending accounts. The company aggregates healthcare information from various sources to streamline claims submission, significantly reducing manual processing time and costs for TPAs. By providing online tools for managing the reimbursement process, FlexMinder aims to improve the user experience for consumers utilizing their flexible spending arrangements. In 2013, the company secured $1.4 million in Series AA financing to support its growth initiatives and was selected for the TechStars incubator program. As of January 2017, FlexMinder operates as a subsidiary of Jelleyvision Lab Inc.
Resolve Therapeutics, LLC is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing innovative therapies for autoimmune diseases, particularly systemic lupus erythematosus and Sjögren's syndrome. Established in 2010, the company is advancing its lead biologic compounds, including RSLV-132, a mono-specific nuclease Fc-fusion protein designed to target and eliminate immune complexes, thereby reducing kidney damage and interferon activation. Additionally, Resolve Therapeutics is progressing RSLV-133, a bi-specific Fc-nuclease fusion protein that integrates dual nuclease activities into a single therapeutic molecule. The company's research is rooted in significant discoveries made by Dr. Keith Elkon and Dr. Jeff Ledbetter at the University of Washington School of Medicine, with a commitment to enhancing the quality of life for patients affected by these challenging conditions.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies to improve treatment for migraine patients in the United States, Australia, and Ireland. The company's lead candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38 for similar purposes, and Clazakizumab, which targets the pro-inflammatory cytokine interleukin-6 and has completed two Phase 2b trials. In addition to its product development efforts, Alder engages in strategic collaborations, notably with CSL Limited for advancing clazakizumab as a treatment for solid organ transplant rejection. Incorporated in 2002 and headquartered in Bothell, Washington, Alder operates primarily in the United States, where it generates most of its revenue.
Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.
Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.
Oncofactor is a Seattle, Washington-based developer of cancer therapeutics that disrupt signaling pathways between tumors and the immune system.
Mirador Biomedical's team of experienced entrepreneurs and seasoned medical device professionals are partnering with an exceptional group of physicians and scientists to develop innovative, cost effective devices that provide physiological feedback to alleviate doubt and uncertainty during common medical procedures.
Nimbic is a provider of cloud-based electronic design automation (EDA) solutions specializing in electromagnetic integrity for the microelectronics industry. Headquartered in Mountain View, California, the company offers services that address challenges related to signal integrity, power integrity, and electromagnetic interference across various design domains, including microprocessors, FPGAs, memory, wireless RF systems, and high-speed channels. Nimbic's nCloud solution enables efficient chip-package-system co-design, significantly reducing time-to-market and costs for its clients. The company's advanced technology delivers high-capacity, rapid 3D simulations throughout the entire design cycle, maintaining exceptional accuracy and performance. Nimbic serves a global clientele that includes notable companies such as Texas Instruments, Renesas, Toshiba, Tabula, and Panasonic.
Mirador Biomedical's team of experienced entrepreneurs and seasoned medical device professionals are partnering with an exceptional group of physicians and scientists to develop innovative, cost effective devices that provide physiological feedback to alleviate doubt and uncertainty during common medical procedures.
Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.
Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.
Skytap, Inc. specializes in providing cloud-based development and testing environments aimed at migrating and modernizing enterprise applications globally. The company's primary offering, Skytap Cloud, allows for self-service access to production-like environments, facilitating more frequent code testing for development and testing teams. Skytap’s platform supports organizations in transitioning to modern software delivery methods by enabling the rapid migration of traditional workloads to the cloud and fostering the adoption of agile and DevOps practices. This approach helps businesses enhance their application development efficiency and integrate new cloud architectures. Additionally, Skytap provides a range of services including cloud migration, application modernization, training, and strategic consulting. Founded in 2006 and headquartered in Seattle, Washington, Skytap also maintains locations in Toronto, Canada, and London, United Kingdom.
Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that specializes in the development and manufacture of proteins and enzymes for various applications, including pharmaceuticals, polymers, and industrial chemicals. Founded in 2008, Arzeda utilizes advanced technology that combines physics-based protein design with artificial intelligence algorithms to create and validate new designer proteins and enzymes. The company aims to provide innovative solutions that offer competitive performance, cost efficiency, and sustainability, addressing the needs of clients in diverse industries.
Corensic is a software company that specializes in providing quality tools designed to enhance the reliability of applications in multi-core environments. Founded in late 2008, and initially known as PetraVM, the company aims to assist developers and IT organizations in building higher quality software. Its flagship product, Jinx, is a tool that helps improve application performance by intentionally exposing hard-to-find concurrency bugs during the debugging process. Corensic's offerings include a visual studio extension and a command-line utility that enable developers and testers to detect and resolve catastrophic concurrency issues in both Windows and Linux applications. Backed by investors such as Madrona Ventures and the Washington Research Foundation, Corensic is committed to supporting the multi-core revolution in software development.
Nimbic is a provider of cloud-based electronic design automation (EDA) solutions specializing in electromagnetic integrity for the microelectronics industry. Headquartered in Mountain View, California, the company offers services that address challenges related to signal integrity, power integrity, and electromagnetic interference across various design domains, including microprocessors, FPGAs, memory, wireless RF systems, and high-speed channels. Nimbic's nCloud solution enables efficient chip-package-system co-design, significantly reducing time-to-market and costs for its clients. The company's advanced technology delivers high-capacity, rapid 3D simulations throughout the entire design cycle, maintaining exceptional accuracy and performance. Nimbic serves a global clientele that includes notable companies such as Texas Instruments, Renesas, Toshiba, Tabula, and Panasonic.
GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado.
Hyperion Therapeutics is a biopharmaceutical company based in Brisbane, California, specializing in the development and commercialization of treatments for orphan diseases. The company focuses on therapeutics for urea cycle disorders (UCD) and hepatic encephalopathy, offering products such as RAVICTI, a nitrogen-binding agent for managing UCD in both adults and children, as well as BUPHENYL and AMMONAPS for specific UCD subtypes. In addition to its existing therapies, Hyperion is developing glycerol phenylbutyrate, an active component of RAVICTI, aimed at treating hepatic encephalopathy. Founded in 2006, Hyperion Therapeutics operates as a subsidiary of Horizon Pharma USA and is committed to addressing the needs of underserved patient populations in the United States and internationally.
Skytap, Inc. specializes in providing cloud-based development and testing environments aimed at migrating and modernizing enterprise applications globally. The company's primary offering, Skytap Cloud, allows for self-service access to production-like environments, facilitating more frequent code testing for development and testing teams. Skytap’s platform supports organizations in transitioning to modern software delivery methods by enabling the rapid migration of traditional workloads to the cloud and fostering the adoption of agile and DevOps practices. This approach helps businesses enhance their application development efficiency and integrate new cloud architectures. Additionally, Skytap provides a range of services including cloud migration, application modernization, training, and strategic consulting. Founded in 2006 and headquartered in Seattle, Washington, Skytap also maintains locations in Toronto, Canada, and London, United Kingdom.
HaloSource, Inc. innovates and integrates technologies to deliver clean drinking water solutions to partners with trusted brands around the world. The Company works with scientists and industry experts across the globe in search of new ways to improve drinking water quality and has been awarded more than 30 patents for its ground-breaking chemistries, which provide safe drinking water for more than 10 million consumers globally. The Company's class-leading HaloPure? Drinking Water technology has the highest global certifications, including registration with the US EPA. With the addition of our lead removal media to the product line, the Company's product offerings will continue to broaden to address more issues in more market segments around the world. With technologies that earn the highest regulatory certifications, a stable of strong strategic relationships and a pipeline of new products and performance, the Company expects to be well positioned to capitalise on the opportunities available to it in the residential water treatment market. The Company is headquartered in Seattle, WA, USA which is also its main country of operation. The Company's activities and assets are more fully described on its website at www.halosource.com. The Company is seeking to re-domicile from Washington State to the BVI.
Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics for a range of indications, including inflammation, complement-mediated diseases, and central nervous system disorders. The company is known for its commercial product, OMIDRIA, which is used during cataract surgery in the United States. Omeros has several clinical programs, with its lead candidate, Narsoplimab, in Phase III trials for conditions such as thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other clinical programs include OMS405 for opioid and nicotine addiction and OMS527 for addiction and compulsive disorders. The company also has a robust pipeline of preclinical programs targeting various disorders, including MASP-3 for paroxysmal nocturnal hemoglobinuria and a GPCR platform aimed at treating a broad range of diseases. Omeros was incorporated in 1994 and remains dedicated to addressing significant unmet medical needs.
Targeted Growth is a crop-biotech company developing yield-enhanced and quality-improved products for the agriculture and energy industries. TGI's crop biotechnology increases the yields in multiple crops and it focuses on those crops such as corn, soy, and canola that produce the raw material that enables farmers to use them for the production of renewable fuels such as ethanol and biodiesel.
Farecast is a fare-prediction startup founded in 2003 that helps travelers decide whether to purchase airline tickets or wait for potentially lower fares. The company utilizes analysis of 175 billion points of historical airfare data to provide intelligent predictions, claiming a success rate of 70-75% in forecasting price trends up to a week in advance. Farecast distinguishes itself from competitors by being the only service that offers these predictive insights. Additionally, the platform has expanded its offerings to include hotel deals, displaying results from various travel search sites on a map, which highlights pricing information. This allows users to quickly identify overpriced hotels, marked in blue, and attractively priced options, marked in red, ultimately helping travelers save money on their travel expenses.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies to improve treatment for migraine patients in the United States, Australia, and Ireland. The company's lead candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38 for similar purposes, and Clazakizumab, which targets the pro-inflammatory cytokine interleukin-6 and has completed two Phase 2b trials. In addition to its product development efforts, Alder engages in strategic collaborations, notably with CSL Limited for advancing clazakizumab as a treatment for solid organ transplant rejection. Incorporated in 2002 and headquartered in Bothell, Washington, Alder operates primarily in the United States, where it generates most of its revenue.
VLST Corporation is a privately held biotechnology company that has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases. The VLST platform uses novel bioinformatics and state-of-the-art proteomics, to identify viral genes whose protein products function as immunomodulatory agents. The resulting product candidates will be either human homologues to these virulence factors or monoclonal antibodies that mimic the function of the virulence gene products. This approach allows for the efficient identification of high quality, pre-validated drug targets for the treatment of autoimmune and inflammatory disorders. The Company's technology has identified potential product candidates for the treatment of disorders such as multiple sclerosis, lupus, psoriasis, rheumatoid arthritis and diabetes.
Targeted Growth is a crop-biotech company developing yield-enhanced and quality-improved products for the agriculture and energy industries. TGI's crop biotechnology increases the yields in multiple crops and it focuses on those crops such as corn, soy, and canola that produce the raw material that enables farmers to use them for the production of renewable fuels such as ethanol and biodiesel.
Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.
Teranode's software and services support both executives and researchers on research and development decisions. Its goal has been to change the role computing plays in Life Sciences by providing flexible, scientist-driven technology that automates experiment workflow, manages experiment and biological data, unifies data into user specific views to improve product life cycle.
Farecast is a fare-prediction startup founded in 2003 that helps travelers decide whether to purchase airline tickets or wait for potentially lower fares. The company utilizes analysis of 175 billion points of historical airfare data to provide intelligent predictions, claiming a success rate of 70-75% in forecasting price trends up to a week in advance. Farecast distinguishes itself from competitors by being the only service that offers these predictive insights. Additionally, the platform has expanded its offerings to include hotel deals, displaying results from various travel search sites on a map, which highlights pricing information. This allows users to quickly identify overpriced hotels, marked in blue, and attractively priced options, marked in red, ultimately helping travelers save money on their travel expenses.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies to improve treatment for migraine patients in the United States, Australia, and Ireland. The company's lead candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38 for similar purposes, and Clazakizumab, which targets the pro-inflammatory cytokine interleukin-6 and has completed two Phase 2b trials. In addition to its product development efforts, Alder engages in strategic collaborations, notably with CSL Limited for advancing clazakizumab as a treatment for solid organ transplant rejection. Incorporated in 2002 and headquartered in Bothell, Washington, Alder operates primarily in the United States, where it generates most of its revenue.
In the spring of 2002, Vanson, Inc. and HaloSource Corp. merged to form Vanson HaloSource, Inc. in order to expand opportunities for product commercialization by capitalizing on manufacturing facilities, distribution channels and intellectual property. Vanson’s cGMP certified manufacturing facility, located in Western Washington accommodates the production of most of Vanson HaloSource's products. The management team and a talented pool of chemists, biochemists and microbiologists are working together to create and expand the Company’s broad spectrum of applications. Today the Company holds dozens of patents and patents pending on a broad range of products that are distributed to the pool and spa, wastewater treatment, and biomedical industries. The Company has a substantial pipeline of proprietary new products in research and development, and a growing number of strategic alliances with prestigious companies to manufacture and market value-added chitin/chitosan-based and antimicrobial products.
Farecast is a fare-prediction startup founded in 2003 that helps travelers decide whether to purchase airline tickets or wait for potentially lower fares. The company utilizes analysis of 175 billion points of historical airfare data to provide intelligent predictions, claiming a success rate of 70-75% in forecasting price trends up to a week in advance. Farecast distinguishes itself from competitors by being the only service that offers these predictive insights. Additionally, the platform has expanded its offerings to include hotel deals, displaying results from various travel search sites on a map, which highlights pricing information. This allows users to quickly identify overpriced hotels, marked in blue, and attractively priced options, marked in red, ultimately helping travelers save money on their travel expenses.
Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.
Noting the growing trends in group travel, [Expedia](http://www.crunchbase.com/organization/expedia) and [Microsoft](http://www.crunchbase.com/organization/microsoft) vets founded TripHub in 2005. Based on the philosophy that "planning should be as fun as the trip," TripHub provides users with many different ways to facilitate group travel. Recently, Triphub [teamed up](http://about.triphub.com/2006/01/plan-talk-among.html) with [Orbitz](http://www.orbitz.com) to provide a ["powered by Triphub"](http://about.triphub.com/partners/index.html)group travel option. They are funded by Madrona Venture Group and other private investors. ###TripHub entered the deadpool on August 25, 2008.###